Neuroscios Gmbh

Biochromix Newco Ab

Disruptive Pharma Ab

Cpl Bcx Pharma Ab

Peter Åsberg

Kristin Hammer

Johan Olsson

Andreas Åslund

Peter Konradsson

Leif Johansson

Sara Frykstrand Ångström

Ottilia Arvén

Tuulikki Lindmark

Anna Herland

Martin Henriksson

Andreas ÅSlund

A solid and substantially amorphous admixture comprising Sorafenib as active pharmaceutical ingredient (API) and a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC), a method for the manufacture thereof, and an oral pharmaceutical formulation comprising the solid substantially amorphous admixture.

Amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate

The present invention relates to novel chemical compounds formula (I) (C)&#x2014;B-(A)-B&#x2014;(C)(I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-membered heteroaromatic rings, and for a terminal ring B or C also from bicyclic heteroaromatic fused rings having seven to ten ring members, wherein the bond between at least two of the rings A to C may be replaced by a carbonyl group (&#x2014;CO&#x2014;), wherein at least two of the rings A to C are substituted with one or two groups R, and wherein each ring A to C further optionally is substituted with one or two groups R. The compounds are useful in therapy, especially therapy of a mammal suffering from a disease involving misfolded or aggregated forms of proteins.

Substituted aromatic oligomers

A compound is provided of the formula wherein each u is independently selected from 0 and 1; each Rand Ris independently selected from carboxy, carboxyalkyl, alkoxycarbonylalkyl, aminoalkyl, (amino)(carboxy)alkyl and (amino)(carboxy)alkoxy; or a pharmaceutically acceptable salt thereof.

Substituted thiophene pentamers

Growing community of inventors

Stockholm, Sweden

Peter Åsberg